DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center ( COCD ) for its CARA System application

BROSSARD, Quebec, April 16, 2025 ( GLOBE NEWSWIRE )– Diagnos Inc. ( “DIAGNOS” or the” Corporation” ) ( TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A ), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence ( AI), announces major advances in Cybersecurity certification by the Cyber Defense Operations Center ( COCD ) for its CARA System application.

As part of its ongoing ISO 27001 certification process, DIAGNOS is pleased to announce that its CARA System app has recently undergone a series of extensive penetration assessments, in accordance with the security needs of the Quebec Ministry of Health. The risks identified during these tests were speedily corrected following regression testing carried out in early March 2025. These measures enabled DIAGNOS to receive a positive assessment of CARA’s security posture from the Cyber Defense Operational Center ( COCD ), underlining compliance with stringent cybersecurity standards.

An official warning has been sent to Quebec’s medical institutions, including CISSS and CIUSSS, as well as CHUM, authorizing them to connect CARA into their projects.

” Protecting personal information is at the center of our responsibility to our customers. The successful completion of our intrusion test validated by Quebec’s Centre opérationnel de cybersécurité gouvernemental ( COCD ) is indisputable proof of the high level of security of our CARA application. This exam marks a crucial step in our travel to obtain ISO 27001 documentation. The planned validation audit may be crucial in confirming our continuous efforts and dedication to the highest standards of cybersecurity. Our users can have complete confidence in our thorough requirements to protect their information. André Larente, CEO DIAGNOS&nbsp”,

In addition, DIAGNOS is even proud to announce that its ISO 27001 certification process is progressing according to plan. Audit dates with documentation body Intertek have been set, and an update will be published over the summer.

About DIAGNOS
DIAGNOS is a publicly traded American company dedicated to early recognition of essential eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to care clinicians to improve clinical reliability, optimize workflows, and improve patient outcomes on a global scale.

Additional information is available at www. diagnos.com &nbsp, and&nbsp, www. sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.